Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Tax Provisions (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Tax Provisions for 5 consecutive years, with $30000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions rose 11.11% year-over-year to $30000.0, compared with a TTM value of $314000.0 through Dec 2025, down 5.14%, and an annual FY2025 reading of $314000.0, down 5.14% over the prior year.
  • Tax Provisions was $30000.0 for Q4 2025 at Aligos Therapeutics, down from $56000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $757000.0 in Q2 2023 and bottomed at -$58000.0 in Q4 2021.
  • Average Tax Provisions over 5 years is $84350.0, with a median of $44000.0 recorded in 2021.
  • Peak annual rise in Tax Provisions hit 1510.64% in 2023, while the deepest fall reached 161.22% in 2023.
  • Year by year, Tax Provisions stood at -$58000.0 in 2021, then soared by 184.48% to $49000.0 in 2022, then plummeted by 161.22% to -$30000.0 in 2023, then skyrocketed by 190.0% to $27000.0 in 2024, then increased by 11.11% to $30000.0 in 2025.
  • Business Quant data shows Tax Provisions for ALGS at $30000.0 in Q4 2025, $56000.0 in Q3 2025, and $185000.0 in Q2 2025.